Cargando…

Comparative efficacy and safety of different regimens of ranibizumab for neovascular age-related macular degeneration: a network meta-analysis of randomised controlled trials

OBJECTIVE: To give a comprehensive efficacy and safety ranking of different therapeutic regimens of ranibizumab for neovascular age-related macular degeneration (nAMD). DESIGN: A systematic review and network meta-analysis. METHODS: The PubMed, Embase, Cochrane Central Register of Controlled Trials,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Xinyu, Meng, Lihui, Chen, Youxin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Ophthalmology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925869/ https://www.ncbi.nlm.nih.gov/pubmed/33550238 http://dx.doi.org/10.1136/bmjopen-2020-040906

Ejemplares similares

Subretinal Neovascular Membrane in Wet Age-Related Macular Degeneration Managed With Intravitreal Ranibizumab
por: Sharma, Tanishq S, et al.
Publicado: (2021)

Ranibizumab therapy for predominantly hemorrhagic neovascular age-related macular degeneration
por: Dikmetas, Ozlem, et al.
Publicado: (2022)

A Comparative Study of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration: 12-Month Outcomes of Polish Therapeutic Program in Non-Tertiary Institution
por: Skrzypczak, Tomasz, et al.
Publicado: (2021)

Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration
por: Chen, Youxin, et al.
Publicado: (2012)

Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006)

Patient perspectives and barriers in the treatment of neovascular age-related macular degeneration in Denmark: a qualitative study
por: Thinggaard, Benjamin Sommer, et al.
Publicado: (2023)

The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited
por: Brown, Gary C., et al.
Publicado: (2017)

Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
por: Razavi, Sam, et al.
Publicado: (2021)

Safety and efficacy of an artificial intelligence-enabled decision tool for treatment decisions in neovascular age-related macular degeneration and an exploration of clinical pathway integration and implementation: protocol for a multi-methods validation study
por: Hogg, Henry David Jeffry, et al.
Publicado: (2023)

Eligibility for faricimab in a real-world neovascular age-related macular degeneration population: a cross-sectional study
por: Jern, Iréne, et al.
Publicado: (2022)

Faricimab Effectively Resolves Intraretinal Fluid and Preserves Vision in Refractory, Recalcitrant, and Nonresponsive Neovascular Age-Related Macular Degeneration
por: Cheng, Anny M, et al.
Publicado: (2023)

Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials
por: Kodjikian, Laurent, et al.
Publicado: (2014)

Emotional and physical experiences of people with neovascular age-related macular degeneration during the injection process in Germany: a qualitative study
por: Thier, Anne, et al.
Publicado: (2022)

Incidence and prevalence of neovascular age-related macular degeneration: 15-year epidemiological study in a population-based cohort in Finland
por: Korva-Gurung, Ida, et al.
Publicado: (2023)

Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research
por: Wolf, Armin, et al.
Publicado: (2014)

FENETRE study: quality-assured follow-up of quiescent neovascular age-related macular degeneration by non-medical practitioners: study protocol and statistical analysis plan for a randomised controlled trial
por: Learoyd, Annastazia E, et al.
Publicado: (2021)

Investigation of time to first presentation and extrahospital factors in the treatment of neovascular age-related macular degeneration: a retrospective cross-sectional study
por: Sim, Peng Yong, et al.
Publicado: (2017)

TANDEM TRIAL: a factorial randomised controlled trial of dose and review schedule of bevacizumab (Avastin) for neovascular macular degeneration in the East Midlands
por: Foss, Alexander, et al.
Publicado: (2020)

Bevacizumab versus Ranibizumab on As-Needed Treatment Regimen for Neovascular Age-Related Macular Degeneration in Turkish Patients
por: Ozkaya, Abdullah, et al.
Publicado: (2013)

Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
por: Hurley, Susan F, et al.
Publicado: (2008)

Treatment of neovascular age-related macular degeneration: insights into drug-switch real-world from the Berlin Macular Registry
por: Riemer, Tommes, et al.
Publicado: (2023)

Dietary intervention in patients with age-related macular degeneration: protocol for a randomised controlled trial
por: Tang, Diana, et al.
Publicado: (2019)

Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis
por: Regnier, Stephane A, et al.
Publicado: (2015)

Reduction in choroidal thickness of macular area in polypoidal choroidal vasculopathy patients after intravitreal ranibizumab therapy
por: Nishide, Tadayuki, et al.
Publicado: (2013)

Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial
por: Sahni, Jayashree, et al.
Publicado: (2020)

Antiplatelet and anticoagulant therapy in patients with submacular hemorrhage caused by neovascular age-related macular degeneration
por: Weber, Constance, et al.
Publicado: (2022)

Intravitreal Bevacizumab for Choroidal Neovascular Membrane in Macular Telangiectasia Type 2
por: Gonzalez Martinez, Orlando G, et al.
Publicado: (2023)

Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen
por: Mantel, Irmela, et al.
Publicado: (2014)

Randomised, Double-blind, Comparative Clinical Study of New Ranibizumab Biosimilar in Neovascular (Wet) Age-Related Macular Degeneration
por: Apsangikar, Prasad, et al.
Publicado: (2021)

Ranibizumab port delivery system in neovascular age-related macular degeneration
por: Chandrasekaran, Priya R., et al.
Publicado: (2022)

Estimating excess visual loss from neovascular age-related macular degeneration in the UK during the COVID-19 pandemic: a retrospective clinical audit and simulation model
por: Thomas, Darren S, et al.
Publicado: (2022)

Self-Examination Low-Cost Full-Field Optical Coherence Tomography (SELFF-OCT) for neovascular age-related macular degeneration: a cross-sectional diagnostic accuracy study
por: von der Burchard, Claus, et al.
Publicado: (2022)

Is Spectral-Domain Optical Coherence Tomography Essential for Flexible Treatment Regimens with Ranibizumab for Neovascular Age-Related Macular Degeneration?
por: Ozkaya, Abdullah, et al.
Publicado: (2013)

Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis
por: Wang, Luping, et al.
Publicado: (2018)

Effectiveness of Community versus Hospital Eye Service follow-up for patients with neovascular age-related macular degeneration with quiescent disease (ECHoES): a virtual non-inferiority trial
por: Reeves, Barnaby C, et al.
Publicado: (2016)

Repeatability of retinal thickness and volume metrics in neovascular age-related macular degeneration using the topcon 3doct-1000
por: Tah, Vikas, et al.
Publicado: (2014)

Healthcare experiences of patients with age-related macular degeneration: have things improved? Cross-sectional survey responses of Macular Society members in 2013 compared with 1999
por: Boxell, Emily M, et al.
Publicado: (2017)

Ranibizumab for choroidal neovascular membrane in a rare case of Bietti's crystalline dystrophy: A case report
por: Nachiappan, Kasinathan, et al.
Publicado: (2012)

Ranibizumab for choroidal neovascularization secondary to pseudoxanthoma elasticum: 4-year results from the PIXEL study in France
por: Mimoun, Gérard, et al.
Publicado: (2017)

Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration
por: Kaiser, Peter K.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_vql6iok96c49hju68k8cnrer02